The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

Blueprint Medicines Reports Second Quarter 2022 Results

2022-08-10T21:02:03-05:00August 10th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022. "We are now one year into the AYVAKIT launch in advanced systemic mastocytosis (SM) and continue to see a significant expansion of our prescriber base as well as strong patient demand, reinforcing [...]

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

2022-08-10T20:54:23-05:00August 10th, 2022|

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a [...]

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

2022-08-10T20:50:25-05:00August 10th, 2022|

Metabolon, Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests. Metabolon will analyze Mayo Clinic patient clinical samples across multiple cohorts to look for disease biomarkers. New [...]

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

2022-08-10T20:46:27-05:00August 10th, 2022|

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and [...]

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

2022-08-10T20:42:15-05:00August 10th, 2022|

Since its $400 million acquisition of telehealth platform developer and telepharmacy services company Lemonaid Health last November, 23andMe has started expanding beyond its core consumer genetic testing into a new business line called its genomic health service. "Developing our genomic health service for our customers remains a high priority for our consumer business," CFO [...]

Myocardial Infarction Features Found With Multiomic Molecular Map

2022-08-10T20:39:10-05:00August 10th, 2022|

A team from Germany, Slovenia, the Netherlands, UK, and US turned to single-cell gene expression profiling and other omics approaches to put together a "molecular map" of myocardial infarction effects — work that is expected to improve investigators' understanding of the coronary heart condition. With the help of spatial gene expression profiling, single-nucleus RNA [...]

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

2022-08-10T20:31:51-05:00August 10th, 2022|

Invitae reported after the market close on Tuesday that its total second quarter revenues rose almost 18 percent year over year, to $136.6 million, just shy of analysts' estimate of $136.85 million, and driven largely by the company's oncology business. Invitae CFO Roxi Wen said on a conference call after the release of the [...]

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

2022-08-10T20:27:43-05:00August 10th, 2022|

10x Genomics said on Monday after the close of the market that it is lowering its 2022 revenue guidance by approximately $100 million. The Pleasanton, California-based single-cell and spatial omics analysis technologies firm now expects revenue in the range of $500 million to $520 million, representing growth of 2 percent to 6 percent over [...]

Go to Top